The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 601–700 of 1,008
Makam, A. N., & Nguyen, O. K. (2017) · Circulation · doi:10.1161/circulationaha.116.022622 · Cited by 52
Alcocer, L. A., Bryce, A., Brasil, D., Lara-Terán, J. J., Cortes, J. M., Quesada, D., & Rodriguez, P. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00605-5 · Cited by 71
“In the IRMA-2 study in hypertensive patients with T2D and micro-albuminuria, irbesartan significantly reduced the risk of diabetic nephropathy compared with placebo ( p 0.001), but there was no significant difference in the incidence of non-fatal cardiovascular events ( p = 0.11) [88].”
BackgroundInfluentialThe role of renin–angiotensin– aldosterone system inhibition in chronic kidney disease
Norris, K. C., & Vaughn, C. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.1.51 · Cited by 58
Kusumoto, K., Igata, H., Ojima, M., Tsuboi, A., Imanishi, M., Yamaguchi, F., Sakamoto, H., Kuroita, T., Kawaguchi, N., Nishigaki, N., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.014 · Cited by 55
Viswanathan, V., Tilak, P., & Kumpatla, S. (2012) · PubMed Central · Cited by 80
Lindhardt, M. K., Persson, F., Oxlund, C. S., Jacobsen, I. A., Zürbig, P., Mischak, H., Rossing, P. R., & Heerspink, H. J. L. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw406 · Cited by 54
“Clinical trials have shown a beneficial effect on mortality and progression to end-stage renal disease using ACEis or ARBs where albuminuria-lowering effects were evident [29, 30].”
BackgroundPrevention of Loss of Renal Function Over Time in Patients with Diabetic Nephropathy
Barnett, A. H. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.013 · Cited by 52
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program
Unger, T. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00230-3 · Cited by 56
Schram, M. T., van Ittersum, F. J., de Man, A., van Dijk, R. A. J. M., Schalkwijk, C., IJzerman, R. G., Twisk, J. W. R., & Stehouwer, C. D. A. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001812 · Cited by 53
Smith, D. H. G. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80056-x · Cited by 52
Microalbuminuria in diabetes mellitus.
Tobe, S. W., McFarlane, P. A., & Naimark, D. M. (2002) · Europe PMC (PubMed Central) · Cited by 61
Improved survival rate in patients with diabetes and end-stage renal disease in Denmark
Sørensen, V. R., Mathiesen, E. R., Heaf, J. G., & Feldt‐Rasmussen, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0612-5 · Cited by 58
Weinberg, A. J., Zappe, D., Ashton, M., & Weinberg, M. S. (2004) · American Journal of Nephrology · doi:10.1159/000078950 · Cited by 52
Lewis, E. J. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)03007-8 · Cited by 52
Type 2 diabetes: RENAAL and IDNT–the emergence of new treatment options
Sica, D. A., & Bakris, G. L. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.00749.x · Cited by 49
Senolytic combination of dasatinib and quercetin attenuates renal damage in diabetic kidney disease
Guo, X., Si, W., Wang, J., Zeng, X., Yu, H., Chen, Y., Zhu, X., & Li, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155705 · Cited by 63
Miyata, T., & de Strihou, C. V. Y. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.08.010 · Cited by 57
El-Samahy, M. H., Adly, A., Elhenawy, Y. I., Ismail, E. G. M., Pessar, S. A., Mowafy, M. E., Saad, M. S., & Mohammed, H. H. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.10.014 · Cited by 59
OGAWA, S., TAKEUCHI, K., MORI, T., NAKO, K., TSUBONO, Y., & ITO, S. (2007) · Hypertension Research · doi:10.1291/hypres.30.325 · Cited by 51
Lopes, A. A. (2004) · Advances in Renal Replacement Therapy · doi:10.1053/j.arrt.2003.10.006 · Cited by 52
Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?
Volpe, M., Ruilope, L. M., McInnes, G. T., Waeber, B., & Weber, M. A. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001831 · Cited by 54
Rodby, R. A., Chiou, C.-F., Borenstein, J. E., Smitten, A. L., Sengupta, N., Palmer, A. J., Roze, S., Annemans, L., Simon, T. A., Chen, R. S., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80208-4 · Cited by 51
Segura, J., Praga, M., Campo, C., Rodicio, J. L., & Ruilope, L. M. (2003) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2003.007 · Cited by 51
Plasma sRAGE Is Independently Associated With Urinary Albumin Excretion in Type 2 Diabetes
Humpert, P. M., Kopf, S., Djuric, Z., Wendt, T., Morcos, M., Nawroth, P. P., & Bierhaus, A. (2006) · Diabetes Care · doi:10.2337/dc05-2478 · Cited by 51
Ishibashi, Y., Matsui, T., Takeuchi, M., & Yamagishi, S. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.11.001 · Cited by 51
Searching for New Biomarkers of Renal Diseases through Proteomics
Konvalinka, A., Scholey, J. W., & Diamandis, E. P. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.165969 · Cited by 55
Prevention of Progression in Diabetic Nephropathy
Hall, P. M. (2006) · Diabetes Spectrum · doi:10.2337/diaspect.19.1.18 · Cited by 59
Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?
Turner, J. M., & Kodali, R. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01352-8 · Cited by 58
Parving, H., & Hovind, P. H. (2002) · Current Hypertension Reports · doi:10.1007/s11906-002-0069-3 · Cited by 52
Self-citationHypertension and Diabetes: Role of the Renin-Angiotensin System
Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.007 · Cited by 59
Olmesartan medoxomil: An angiotensin II-receptor blocker
Brousil, J. A., & Burke, J. M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80066-8 · Cited by 50
Angiotensin blockade for hypertension: a promise fulfilled
Brunner, H. R., & Gavras, H. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08062-5 · Cited by 49
Is it time to measure microalbuminuria in hypertension?
Volpe, M., Cosentino, F., & Ruilope, L. M. (2003) · Journal of Hypertension · doi:10.1097/00004872-200307000-00001 · Cited by 49
Microalbuminuria screening in patients with hypertension: recommendations for clinical practice
Volpe, M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01620.x · Cited by 55
Kim‐Mitsuyama, S., Ogawa, H., Matsui, K., Jinnouchi, T., Jinnouchi, H., Arakawa, K., & for the OSCAR Study Group (2012) · Kidney International · doi:10.1038/ki.2012.326 · Cited by 52
Rutter, M. K., & Nesto, R. W. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr154 · Cited by 58
ESRD and Death after Heart Failure in CKD
Sud, M. K., Tangri, N., Pintilie, M., Levey, A. S., & Naimark, D. M. J. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014030253 · Cited by 49
Kusunoki, H., Taniyama, Y., Azuma, J., Iekushi, K., Sanada, F., Otsu, R., Iwabayashi, M., Okayama, K., Rakugi, H., & Morishita, R. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.176263 · Cited by 53
“17 Mice were divided into 11 groups: (1) sham, (2) UUO-operated mice with no drug treatment (control), (3) UUOoperated mice treated with losartan (3.”
MethodZoja, C., Locatelli, M., Corna, D., Villa, S., Rottoli, D., Nava, V., Verde, R., Piscitelli, F., Marzo, V. D., Fingerle, J., et al. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000442679 · Cited by 49
Heerspink, H. J. L., Persson, F., Brenner, B. M., Chaturvedi, N., Brunel, P., McMurray, J. J. V., Desai, A. S., Solomon, S. D., Pfeffer, M. A., PARVING, H.-H. D., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00469-6 · Cited by 52
Self-citationGoss, C. H., Mayer-Hamblett, N., Kronmal, R. A., & Ramsey, B. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00163-1 · Cited by 48
Bonnet, F., Candido, R., Carey, R. M., Casley, D., Russo, L. M., Osicka, T. M., Cooper, M. E., & Cao, Z. (2002) · Journal of Hypertension · doi:10.1097/00004872-200208000-00025 · Cited by 50
The Role of Sulodexide in the Treatment of Diabetic Nephropathy
Weiss, R., Niecestro, R., & Raz, I. (2007) · Drugs · doi:10.2165/00003495-200767180-00004 · Cited by 48
The Role of Glycosaminoglycans and Sulodexide in the Treatment of Diabetic Nephropathy
Abaterusso, C., & Gambaro, G. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605040-00002 · Cited by 52
Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999
Soedamah‐Muthu, S. S., Colhoun, H. M., Abrahamian, H., Chan, N. N., Mangili, R., Reboldi, G., Fuller, J., & the EURODIAB Prospective Complications Study Group (2002) · Diabetologia · doi:10.1007/s00125-002-0914-6 · Cited by 51
How Reliable Is Estimation of Glomerular Filtration Rate at Diagnosis of Type 2 Diabetes?
Chudleigh, R. A., Dunseath, G., Evans, W., Harvey, J. N., Evans, P., Ollerton, R., & Owens, D. R. (2007) · Diabetes Care · doi:10.2337/dc06-1688 · Cited by 49
Malik, R. A., Schofield, I. J., Izzard, A. S., Austin, C., Bermann, G., & Heagerty, A. M. (2005) · Hypertension · doi:10.1161/01.hyp.0000153305.50128.a1 · Cited by 51
Renin-angiotensin system and atherosclerosis
Grote, K., Drexler, H., & Schieffer, B. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh030 · Cited by 50
Outcome beyond blood pressure control?
Staessen, J. A., Wang, J. G., & Birkenhäger, W. H. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00797-2 · Cited by 51
Verdecchia, P., Gentile, G., Angeli, F., & Reboldi, G. (2012) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712444866 · Cited by 50
“…type 2 diabetes and MicroAlbuminuria (IRMA 2) study established the efficacy of ARBs in reducing the onset of diabetic nephropathy as determined by assessing albuminuria progression over a 2-year 86 http://tac.sagepub.com treatment period [Parving et al. 2001; Staessen et al. 2005; Turnbull, 2003].”
BackgroundResultInfluentialCKD Stage at Nephrology Referral and Factors Influencing the Risks of ESRD and Death
Sud, M. K., Tangri, N., Levin, A., Pintilie, M., Levey, A. S., & Naimark, D. M. J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.008 · Cited by 51
Färbom, P., Wahlstrand, B., Almgren, P., Skrtic, S., Lanke, J., Weiss, L. G., Kjeldsen, S. E., Hedner, T., & Melander, O. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.109264 · Cited by 54
Sensitive polydopamine bi-functionalized SERS immunoassay for microalbuminuria detection
Huang, Z., Zhang, R., Chen, H., Weng, W., Lin, Q., Deng, D., Li, Z., & Kong, J. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111542 · Cited by 47
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 48
A basis for accelerated progression of diabetic nephropathy in Pima Indians
Lemley, K. V. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s83.9.x · Cited by 48
Heart and Kidney: Fatal Twins?
Ritz, E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.012 · Cited by 53
Age distribution and yearly changes in the incidence of ESRD in Japan
Yamagata, K., Takahashi, H., Suzuki, S., Mase, K., Hagiwara, M., Shimizu, Y., Hirayama, K., Kobayashi, M., Narita, M., & Kôyama, A. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.11.005 · Cited by 48
Antagonistes des r??cepteurs de l???angiotensine II
Corvol, P. L., & Plouin, P. (2002) · Drugs · doi:10.2165/00003495-200262991-00006 · Cited by 48
Diabetic renal disease: from recent studies to improved clinical practice
Mogensen, C. E., & Cooper, M. E. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01121.x · Cited by 49
Gallo, G., Volpe, M., & Rubattu, S. D. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s337640 · Cited by 62
Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
Ardhanari, S., Alpert, M., & Aggarwal, K. B. (2014) · PubMed · Cited by 57
Reduction of proteinuria with angiotensin receptor blockers
Galle, J. C. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0806 · Cited by 49
The role of renin angiotensin system inhibition in kidney repair
van der Meer, I. M., Cravedi, P., & Remuzzi, G. (2010) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-3-7 · Cited by 52
Onuigbo, M. A. C. (2010) · Renal Failure · doi:10.3109/0886022x.2010.502608 · Cited by 49
New Therapies for the Treatment of Renal Fibrosis
Liu, F., & Zhuang, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_31 · Cited by 51
Woodward, A., Wallymahmed, M., Wilding, J. P. H., & Gill, G. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01889.x · Cited by 51
Rosen, A. B., Karter, A. J., Liu, J. Y., Selby, J. V., & Schneider, E. C. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30264.x · Cited by 50
Current and emerging treatment options for the elderly patient with chronic kidney disease
Fassett, R. G. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s39763 · Cited by 60
A cross-national study of the persistence of antihypertensive medication use in the elderly
van Wijk, B. L., Shrank, W. H., Klungel, O. H., Schneeweiss, S., Brookhart, M. A., & Avorn, J. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e32826308b4 · Cited by 46
Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease
Nistala, R., Wei, Y., Sowers, J. R., & Whaley‐Connell, A. T. (2009) · Translational research · doi:10.1016/j.trsl.2008.12.008 · Cited by 52
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Lytvyn, Y., Godoy, L. C., Scholtes, R. A., van Raalte, D. H., & Cherney, D. Z. I. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1123-8 · Cited by 52
Al-Kuraishy, H. M., Al-Gareeb, A. I., & Al-Nami, M. (2020) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_567_18 · Cited by 46
Chiarelli, F., Marzio, D. D., Santilli, F., Mohn, A., Blasetti, A., Cipollone, F., Mezzetti, A., & Verrotti, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1690 · Cited by 46
Yamada, T., Komatsu, M., Komiya, I., Miyahara, Y., Shima, Y., Matsuzaki, M., Ishikawa, Y., Mita, R., Fujiwara, M., Furusato, N., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2733 · Cited by 56
Progression and regression in renal vascular and glomerular fibrosis
Chatziantoniou, C., Boffa, J., Tharaux, P., Flamant, M., Ronco, P. M., & Dussaule, J. (2004) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2004.00376.x · Cited by 45
New insights into the significance of microalbuminuria
MacIsaac, R. J., Jerums, G., & Cooper, M. E. (2003) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200401000-00012 · Cited by 54
Assessment of kidney function in type 2 diabetes
Chadban, S. J., Howell, M., Twigg, S. M., Thomas, M. C., Jerums, G., Cass, A., Campbell, D. A., Nicholls, K., Tong, A., Mangos, G., et al. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01239.x · Cited by 50
Leporini, C., Pisano, A., Russo, E., D’Arrigo, G., Sarro, G. D., Coppolino, G., & Bolignano, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.001 · Cited by 45
Mega clinical trials which have shaped the RAS intervention clinical practice
Düsing, R. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716644131 · Cited by 47
Early and late scanning electron microscopy findings in diabetic kidney disease
Conti, S., Perico, N., Novelli, R., Carrara, C., Benigni, A., & Remuzzi, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-23244-2 · Cited by 46
Hypertension and antihypertensive treatment of diabetic nephropathy
Ritz, E., & Dikow, R. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0298 · Cited by 49
Seccia, T. M., Maniero, C., Belloni, A. S., Guidolin, D., Pothen, P., Pessina, A. C., & Rossi, G. P. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328309f00a · Cited by 45
Blood Pressure Lowering for the Prevention and Treatment of Diabetic Kidney Disease
Thomas, M. C., & Atkins, R. C. (2006) · Drugs · doi:10.2165/00003495-200666170-00005 · Cited by 53
Prevention and Treatment of Diabetic Nephropathy
Tong, L., & Adler, S. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05876-6.00030-7 · Cited by 47
Zhang, X., Zhang, J., Ren, Y., Sun, R., & Zhai, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1368481 · Cited by 64
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Böhm, M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.013 · Cited by 47
Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis
Evans, K. L., Tuttle, K. R., Folt, D. A., Dawson, T., Haller, S. T., Brewster, P. S., He, W., Jamerson, K., Dworkin, L. D., Cutlip, D. E., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11611113 · Cited by 45
Managing hypertension in type 2 diabetes mellitus
Horr, S. E., & Nissen, S. E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.001 · Cited by 49
Vanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 49
“In addition, at least in type 2 diabetics, nephroprotection was observed even when the drug was started very early in the evolution of the disease, in patients with microalbuminuria [121] or even normoalbuminuria [206].”
BackgroundResultInfluentialSika, M., Lewis, J. B., Douglas, J. G., Erlinger, T. P., Dowie, D., Lipkowitz, M. S., Lash, J. P., Cornish-Zirker, D., Peterson, G., Toto, R. D., et al. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.03.004 · Cited by 46
Zarowitz, B. J., Tangalos, E. G., Hollenack, K. A., & O’Shea, T. (2006) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2006.01.002 · Cited by 47
Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum?
Schmieder, R. E. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220101.57896.cd · Cited by 50
Weber, M. A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200307006-00007 · Cited by 44
Chang, J., Chen, S., Huang, J., Su, H., & Chen, H. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31827981be · Cited by 46
Nagase, M. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0298-8 · Cited by 46
Kamper, M., Tsimpoukidi, O., Chatzigeorgiou, A., Lymberi, M., & Kamper, E. F. (2010) · Translational research · doi:10.1016/j.trsl.2010.05.004 · Cited by 44
Novel Biomarkers for the Progression of Diabetic Nephropathy: Soluble TNF Receptors
Gohda, T., & Tomino, Y. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0385-9 · Cited by 45
Liu, X., Xu, Q., Wang, X., Zhao, Z., Zhang, L., Zhong, L., Li, L., Kang, W., Zhang, Y., & Ge, Z. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.001 · Cited by 44
Cozzolino, M. G., Gentile, G., Mazzaferro, S., Brancaccio, D., Ruggenenti, P. L., & Remuzzi, G. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.379 · Cited by 43
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.